FDA Grants Priority Review to Roche's Gazyva/Gazyvaro for Adults With Primary Membranous Nephropathy
July 15, 2026
July 15, 2026
BASEL, Switzerland, July 15 (TNSjou) -- Roche, a biotech company, issued the following news release:
* * *
FDA grants Priority Review to Roche's Gazyva/Gazyvaro for adults with primary membranous nephropathy
* Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro achieved significantly higher complete remission rates at two years compared to tacrolimus/1
* If approved, Gazyva/Gazyvaro will be the first FDA-a . . .
* * *
FDA grants Priority Review to Roche's Gazyva/Gazyvaro for adults with primary membranous nephropathy
* Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro achieved significantly higher complete remission rates at two years compared to tacrolimus/1
* If approved, Gazyva/Gazyvaro will be the first FDA-a . . .